Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

A Quality Improvement Initiative to Increase the Number of Pediatric Resident Laceration Repairs.

Wagner TL, Dunn MW, Iyer MS, Buckingham D, Spencer SP.

J Grad Med Educ. 2020 Feb;12(1):51-57. doi: 10.4300/JGME-D-19-00331.1.

PMID:
32089794
2.

Increasing optimal coagulation factor dosing in the paediatric emergency department: A quality improvement study.

Drayton Jackson M, Dunn MW, Storey MA, Dunn AL.

Haemophilia. 2019 Mar;25(2):258-263. doi: 10.1111/hae.13693. Epub 2019 Feb 12.

PMID:
30748062
3.

Behavioral and brain evidence for language by ear, mouth, eye, and hand and motor skills in literacy learning.

Berninger VW, Richards TL, Nielsen KH, Dunn MW, Raskind MH, Abbott RD.

Int J Sch Educ Psychol. 2019;7(Suppl 1):182-200. doi: 10.1080/21683603.2018.1458357. Epub 2018 Aug 15.

4.

Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy.

Rose TL, Chism DD, Alva AS, Deal AM, Maygarden SJ, Whang YE, Kardos J, Drier A, Basch E, Godley PA, Dunn MW, Kim WY, Milowsky MI.

Br J Cancer. 2018 Oct;119(7):801-807. doi: 10.1038/s41416-018-0229-0. Epub 2018 Oct 8.

5.

Prostate Cancer Screening.

Dunn MW.

Semin Oncol Nurs. 2017 May;33(2):156-164. doi: 10.1016/j.soncn.2017.02.003. Epub 2017 Mar 23. Review.

PMID:
28343840
6.

Integrating Patient Preference into Treatment Decisions for Men with Prostate Cancer at the Point of Care.

Johnson DC, Mueller DE, Deal AM, Dunn MW, Smith AB, Woods ME, Wallen EM, Pruthi RS, Nielsen ME.

J Urol. 2016 Dec;196(6):1640-1644. doi: 10.1016/j.juro.2016.06.082. Epub 2016 Jun 23.

PMID:
27346032
7.

Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings.

Rose TL, Deal AM, Basch E, Godley PA, Rathmell WK, Kim WY, Whang YE, Dunn MW, Wang A, Chen RC, Nielsen ME, Pruthi RS, Wallen EM, Woods ME, Smith AB, Milowsky MI.

Urol Oncol. 2015 Sep;33(9):386.e1-6. doi: 10.1016/j.urolonc.2015.05.028. Epub 2015 Jun 27.

8.

Improving couples' quality of life through a Web-based prostate cancer education intervention

Song L, Rini C, Deal AM, Nielsen ME, Chang H, Kinneer P, Teal R, Johnson DC, Dunn MW, Mark B, Palmer MH.

Oncol Nurs Forum. 2015 Mar;42(2):183-92. doi: 10.1188/15.ONF.183-192.

9.

Heme oxygenase-2 deletion impairs macrophage function: implication in wound healing.

Bellner L, Marrazzo G, van Rooijen N, Dunn MW, Abraham NG, Schwartzman ML.

FASEB J. 2015 Jan;29(1):105-15. doi: 10.1096/fj.14-256503. Epub 2014 Oct 23.

10.

Visibility in the community helps educate the public about nursing.

Dunn MW.

ONS Connect. 2013 Dec;28(4):60. No abstract available.

PMID:
24400587
11.

Dysregulated heme oxygenase-ferritin system in pterygium pathogenesis.

Fox T, Gotlinger KH, Dunn MW, Lee OL, Milman T, Zaidman G, Schwartzman ML, Bellner L.

Cornea. 2013 Sep;32(9):1276-82. doi: 10.1097/ICO.0b013e3182936915.

12.

Prostate cancer overview.

Dunn MW, Kazer MW.

Semin Oncol Nurs. 2011 Nov;27(4):241-50. doi: 10.1016/j.soncn.2011.07.002. Review.

PMID:
22018403
13.

The role of neutrophils in corneal wound healing in HO-2 null mice.

Marrazzo G, Bellner L, Halilovic A, Li Volti G, Drago F, Dunn MW, Schwartzman ML.

PLoS One. 2011;6(6):e21180. doi: 10.1371/journal.pone.0021180. Epub 2011 Jun 17.

14.

Targeted suppression of HO-2 gene expression impairs the innate anti-inflammatory and repair responses of the cornea to injury.

Bellner L, Patil KA, Castellano K, Halilovic A, Dunn MW, Schwartzman ML.

Mol Vis. 2011 Apr 29;17:1144-52.

15.

Knockdown of heme oxygenase-2 impairs corneal epithelial cell wound healing.

Halilovic A, Patil KA, Bellner L, Marrazzo G, Castellano K, Cullaro G, Dunn MW, Schwartzman ML.

J Cell Physiol. 2011 Jul;226(7):1732-40. doi: 10.1002/jcp.22502.

16.

Biliverdin Rescues the HO-2 Null Mouse Phenotype of Unresolved Chronic Inflammation Following Corneal Epithelial Injury.

Bellner L, Wolstein J, Patil KA, Dunn MW, Laniado-Schwartzman M.

Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3246-53. doi: 10.1167/iovs.10-6219.

17.

Profile of lipid and protein autacoids in diabetic vitreous correlates with the progression of diabetic retinopathy.

Schwartzman ML, Iserovich P, Gotlinger K, Bellner L, Dunn MW, Sartore M, Grazia Pertile M, Leonardi A, Sathe S, Beaton A, Trieu L, Sack R.

Diabetes. 2010 Jul;59(7):1780-8. doi: 10.2337/db10-0110. Epub 2010 Apr 27.

18.

Heme oxygenase-2 deletion causes endothelial cell activation marked by oxidative stress, inflammation, and angiogenesis.

Bellner L, Martinelli L, Halilovic A, Patil K, Puri N, Dunn MW, Regan RF, Schwartzman ML.

J Pharmacol Exp Ther. 2009 Dec;331(3):925-32. doi: 10.1124/jpet.109.158352. Epub 2009 Sep 22.

19.

Exacerbated corneal inflammation and neovascularization in the HO-2 null mice is ameliorated by biliverdin.

Bellner L, Vitto M, Patil KA, Dunn MW, Regan R, Laniado-Schwartzman M.

Exp Eye Res. 2008 Sep;87(3):268-78. doi: 10.1016/j.exer.2008.06.007. Epub 2008 Jun 17.

20.

Heme oxygenase-1 induction attenuates corneal inflammation and accelerates wound healing after epithelial injury.

Patil K, Bellner L, Cullaro G, Gotlinger KH, Dunn MW, Schwartzman ML.

Invest Ophthalmol Vis Sci. 2008 Aug;49(8):3379-86. doi: 10.1167/iovs.07-1515. Epub 2008 Apr 25.

21.

Inhibition of VEGF expression and corneal neovascularization by siRNA targeting cytochrome P450 4B1.

Seta F, Patil K, Bellner L, Mezentsev A, Kemp R, Dunn MW, Schwartzman ML.

Prostaglandins Other Lipid Mediat. 2007 Nov;84(3-4):116-27. Epub 2007 May 21.

22.

Heme oxygenase-2 is a critical determinant for execution of an acute inflammatory and reparative response.

Seta F, Bellner L, Rezzani R, Regan RF, Dunn MW, Abraham NG, Gronert K, Laniado-Schwartzman M.

Am J Pathol. 2006 Nov;169(5):1612-23.

23.

Transfection of cytochrome P4504B1 into the cornea increases angiogenic activity of the limbal vessels.

Mezentsev A, Mastyugin V, Seta F, Ashkar S, Kemp R, Reddy DS, Falck JR, Dunn MW, Laniado-Schwartzman M.

J Pharmacol Exp Ther. 2005 Oct;315(1):42-50. Epub 2005 Jul 11.

PMID:
16009741
24.

Promoter activity and regulation of the corneal CYP4B1 gene by hypoxia.

Mastyugin V, Mezentsev A, Zhang WX, Ashkar S, Dunn MW, Laniado-Schwartzman M.

J Cell Biochem. 2004 Apr 15;91(6):1218-38.

PMID:
15048876
25.

Retinoic acid induces corneal epithelial CYP4B1 gene expression and stimulates the synthesis of inflammatory 12-hydroxyeicosanoids.

Ashkar S, Mesentsev A, Zhang WX, Mastyugin V, Dunn MW, Laniado-Schwartzman M.

J Ocul Pharmacol Ther. 2004 Feb;20(1):65-74.

PMID:
15006160
26.

COX-2 lack of function in hypoxia-induced ocular surface inflammation.

Schwartzman ML, Bonazzi A, Mieyal P, Mezentsev A, Abraham NG, Dunn MW.

Thromb Res. 2003 Jun 15;110(5-6):293-8.

PMID:
14592551
27.

Cytochrome P450-derived eicosanoids mediators of ocular surface inflammation. are.

Laniado-Schwartzman M, Dunn MW.

Adv Exp Med Biol. 2003;525:47-54. No abstract available.

PMID:
12751735
28.

Eicosanoid regulation of vascular endothelial growth factor expression and angiogenesis in microvessel endothelial cells.

Mezentsev A, Seta F, Dunn MW, Ono N, Falck JR, Laniado-Schwartzman M.

J Biol Chem. 2002 May 24;277(21):18670-6. Epub 2002 Mar 18.

29.

Corneal epithelial VEGF and cytochrome P450 4B1 expression in a rabbit model of closed eye contact lens wear.

Mastyugin V, Mosaed S, Bonazzi A, Dunn MW, Schwartzman ML.

Curr Eye Res. 2001 Jul;23(1):1-10.

PMID:
11821980
30.

Detection of endogenous 12-hydroxyeicosatrienoic acid in human tear film.

Mieyal PA, Dunn MW, Schwartzman ML.

Invest Ophthalmol Vis Sci. 2001 Feb;42(2):328-32.

PMID:
11157862
31.

The effect of hypoxia on endogenous corneal epithelial eicosanoids.

Mieyal PA, Bonazzi A, Jiang H, Dunn MW, Schwartzman ML.

Invest Ophthalmol Vis Sci. 2000 Jul;41(8):2170-6.

PMID:
10892859
32.
33.

Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium.

Bonazzi A, Mastyugin V, Mieyal PA, Dunn MW, Laniado-Schwartzman M.

J Biol Chem. 2000 Jan 28;275(4):2837-44.

34.

Retinal pigment epithelial cell-based gene therapy against hemoglobin toxicity.

Abraham NG, Da Silva JL, Dunn MW, Kigasawa K, Shibahara S.

Int J Mol Med. 1998 Apr;1(4):657-63.

PMID:
9852279
35.

Alkali burn-induced synthesis of inflammatory eicosanoids in rabbit corneal epithelium.

Conners MS, Urbano F, Vafeas C, Stoltz RA, Dunn MW, Schwartzman ML.

Invest Ophthalmol Vis Sci. 1997 Sep;38(10):1963-71.

PMID:
9331260
36.

Heme oxygenase induction with attenuation of experimentally induced corneal inflammation.

Laniado-Schwartzman M, Abraham NG, Conners M, Dunn MW, Levere RD, Kappas A.

Biochem Pharmacol. 1997 Apr 25;53(8):1069-75.

PMID:
9175711
37.

Diminished heme oxygenase-1 mRNA expression in RPE cells from diabetic donors as quantitated by competitive RT/PCR.

da Silva JL, Stoltz RA, Dunn MW, Abraham NG, Shibahara S.

Curr Eye Res. 1997 Apr;16(4):380-6.

PMID:
9134328
38.

Hepatosplenic cat-scratch disease and abdominal pain.

Dunn MW, Berkowitz FE, Miller JJ, Snitzer JA.

Pediatr Infect Dis J. 1997 Mar;16(3):269-72.

PMID:
9076813
39.

Adenovirus-mediated heme oxygenase-1 gene transfer into rabbit ocular tissues.

Abraham NG, da Silva JL, Lavrovsky Y, Stoltz RA, Kappas A, Dunn MW, Schwartzman ML.

Invest Ophthalmol Vis Sci. 1995 Oct;36(11):2202-10.

PMID:
7558713
40.

A closed eye contact lens model of corneal inflammation. Part 2: Inhibition of cytochrome P450 arachidonic acid metabolism alleviates inflammatory sequelae.

Conners MS, Stoltz RA, Davis KL, Dunn MW, Abraham NG, Levere RD, Laniado-Schwartzman M.

Invest Ophthalmol Vis Sci. 1995 Apr;36(5):841-50.

PMID:
7706032
41.

A closed eye contact lens model of corneal inflammation. Part 1: Increased synthesis of cytochrome P450 arachidonic acid metabolites.

Conners MS, Stoltz RA, Webb SC, Rosenberg J, Dunn MW, Abraham NG, Laniado-Schwartzman M.

Invest Ophthalmol Vis Sci. 1995 Apr;36(5):828-40.

PMID:
7706031
42.

Modulation of corneal heme oxygenase expression by oxidative stress agents.

Neil TK, Stoltz RA, Jiang S, Laniado-Schwartzman M, Dunn MW, Levere RD, Kappas A, Abraham NG.

J Ocul Pharmacol Ther. 1995 Fall;11(3):455-68.

PMID:
8590277
43.

Effect of metabolic inhibitors on arachidonic acid metabolism in the corneal epithelium: evidence for cytochrome P450-mediated reactions.

Stoltz RA, Conners MS, Dunn MW, Schwartzman ML.

J Ocul Pharmacol. 1994 Spring;10(1):307-17.

PMID:
8207335
44.

Induction of corneal epithelial cytochrome P-450 arachidonate metabolism by contact lens wear.

Davis KL, Conners MS, Dunn MW, Schwartzman ML.

Invest Ophthalmol Vis Sci. 1992 Feb;33(2):291-7.

PMID:
1740358
45.

12(R)-hydroxyeicosatrienoic acid, a potent chemotactic and angiogenic factor produced by the cornea.

Masferrer JL, Rimarachin JA, Gerritsen ME, Falck JR, Yadagiri P, Dunn MW, Laniado-Schwartzman M.

Exp Eye Res. 1991 Apr;52(4):417-24.

PMID:
1709873
46.

Hormonal stimulation of 12(R)-HETE, a cytochrome P450 arachidonic acid metabolite in the rabbit cornea.

Davis KL, Dunn MW, Schwartzman ML.

Curr Eye Res. 1990 Jul;9(7):661-7.

PMID:
2119938
47.

12(R)-hydroxyeicosatetraenoic acid, an endogenous corneal arachidonate metabolite, lowers intraocular pressure in rabbits.

Masferrer JL, Dunn MW, Schwartzman ML.

Invest Ophthalmol Vis Sci. 1990 Mar 1;31(3):535-9.

PMID:
2318592
48.

Ocular effects of a novel cytochrome P-450-dependent arachidonic acid metabolite.

Masferrer JL, Murphy RC, Pagano PJ, Dunn MW, Laniado-Schwartzman M.

Invest Ophthalmol Vis Sci. 1989 Mar;30(3):454-60.

PMID:
2466808
49.

Presence of heme oxygenase and NADPH cytochrome P-450 (c) reductase in human corneal epithelium.

Abraham NG, Lin JH, Dunn MW, Schwartzman ML.

Invest Ophthalmol Vis Sci. 1987 Sep;28(9):1464-72.

PMID:
3114166
50.

Cytochrome P450, drug metabolizing enzymes and arachidonic acid metabolism in bovine ocular tissues.

Schwartzman ML, Masferrer J, Dunn MW, McGiff JC, Abraham NG.

Curr Eye Res. 1987 Apr;6(4):623-30.

PMID:
3107908

Supplemental Content

Support Center